To explore the potential of the above CS‐g‐bPEI NP formulation for translational applications, the formulation was further used in the oral delivery of a human insulin plasmid (INSL4) to reduce the blood glucose levels in mice with STZ‐induced diabetes. This evidence concerns the gene INSL4 and diabetes mellitus.